Peritoneal metastases of rectal and colonic tumor treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: two different diseases

Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis Patients: A Review

“…Four RCTs [16][17][18][19], eight retrospective studies [20][21][22][23][24][25][26][27], and four retrospective and prospective studies [28][29][30][31] were found and selected during the literature screening process. In the study by Verwaal et al and Verwaal et al, randomization was performed centrally by computer and stratified for the presentation site (colon or rectum) [16,17].…”

“…Pallas et al reported that patients with PCI of more than 20 had no chance to survive more than five years. Kecmanovic et al reported that the PCI was equal to or less than 13 in 10 patients, and their median survival time was 16.8 months, statistically significantly lower than the median survival time of 6.9 months for the eight patients with PCI greater than 13 [ 19 , 26 , 27 , 29 ]. The completeness of cytoreduction was found to be a prognostic factor in six studies.…”

“…Three studies were published only in abstract form. Both sexes were represented in the samples, and the patients' ages ranged between 20 and 79 years [20][21][22][23][24][25][26][27]. The remaining four studies were retrospective and prospective analyses.…”

“…Reported outcomes include overall survival, median overall survival, and survival of 1-5 years. Overall survival rates ranged from 63% to 93%; overall median survival ranged from 13 to 60.1 months; a one-year survival rate ranged from 70.7% to 96%; a two-year survival rate ranged from 28.3% to 100%; a three-year survival rate ranged from 20% to 74%; and a five-year survival rate ranged from 0% to 48.5% [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. HIPEC: hyperthermic intraperitoneal chemotherapy, CRS: cytoreductive surgery.…”